Genomind continues to expand presence at industry meetings
CHALFONT, PA – December 13, 2013 – Genomind, a personalized medicine company, is pleased to announce their participation at the American Academy of Anti-Aging (A4M) 21st Annual World Anti-Aging Congress, to be held December 12-15, 2013 in Las Vegas, Nevada at the Venetian Hotel.
As a federally registered 501(c)3 non-profit organization, A4M is the world’s largest non-profit scientific society of physicians and scientists dedicated to the advancement of technology to detect, prevent, and treat aging related disease and to promote research into methods to retard and optimize the human aging process. A4M was established in 1992 and represents over 26,000 physicians and scientists from 120 countries.
A4M is dedicated to educating physicians and scientists and is proud to be in their 21st year of providing Continuing Medical Education conferences on anti-aging issues, regenerative and functional medicine.
To further demonstrate commitment to the future of medicine, shared responsibility for patient outcomes, and transforming health education through innovation, A4M offers Board Certifications and Fellowship Training Programs in disciplines ranging from anti-aging, regenerative and functional medicine to disciplines such as aesthetic medicine, skin cancer and stem cell therapy.
The A4M Congress attracts over 4,000 attendees each year. Genomind will exhibit at Booth #1047A where staff will share new data and new clinical resources focused on Complementary and Integrative medicine strategies that are suggested in the Genecept™ Assay report.
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.
About the Genecept Assay
The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/how-it-works/.
For more information, contact:
Marketing Manager, Genomind